Supplementary Figure S5 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies

Supplemental Figure S5: IFN- production in plasma: MC38 tumor-bearing mice were treated with the indicated doses of mXT301 or unmasked control. Plasma IFN- concentration was measured by MSD assay at indicated time points. The data represent mean ± SEM, N = 3 to 5 mice per group, and IFN- level was assessed by a two-way ANOVA with Bonferroni’s post-hoc pairwise comparison test compared to vehicle (PBS) treated animals (*p < 0.05, **p < 0.005, ****p < 0.0001)